BioCentury
ARTICLE | Finance

Ebb & Flow

September 4, 2006 7:00 AM UTC

The formation of Zogenix and the company's $60 million series A round last week all come from a confluence of events related to a needleless formulation of the migraine compound sumatriptan.

The story starts in January, when Roger Hawley left his post as EVP of commercial and technical operations at InterMune (ITMN) and was looking to start a CNS specialty pharma company. "I got a call from a former colleague at GSK, who said, 'Do you realize that GSK never signed a deal for Imitrex in a new device?'" ...